FDA Issues Warning on Unapproved Biological Products
Wellness clinics must ensure their regenerative products comply with federal licensure to avoid potential seizure of assets.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Do you trust medical treatments marketed online that lack formal FDA approval?
The FDA issued a warning letter to Calibrate IV Hydration after identifying that its umbilical cord-derived and exosome products lack required biological license applications. The agency flagged these products as unapproved new drugs and unlicensed biological products based on a review of the company's website.
Why it matters
The regulatory action highlights the FDA's strict oversight of regenerative medicine marketing, specifically regarding products intended for allogeneic use without premarket approval. Businesses in the wellness and clinical space must ensure all biological offerings comply with federal licensure standards to avoid potential seizure or legal injunctions.
The FDA provided a 15 working day deadline for a written response regarding unapproved drug violations, which the agency identified after reviewing marketing claims on calibrateiv.com. The scope of the investigation covered products marketed for neurology, immunology, and orthopedics.
The players
FDA
The federal agency responsible for protecting public health by regulating the safety, efficacy, and security of biological products and medical devices.
Calibrate IV Hydration
A company operating in the hydration and wellness space that distributes umbilical cord-derived and exosome products.
The details
The FDA determined that the products sold by Calibrate IV Hydration are not intended for homologous use, classifying them as unapproved new drugs and unlicensed biological products. By distributing these materials without an approved biologics license application, the company failed to meet the safety and efficacy standards mandated by the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act.
Timeline
October 2026: The FDA conducted a review of the calibrateiv.com website.
October 13, 2026: The FDA officially issued the warning letter.
15 working days after receipt: The required window for the company to submit its written response.
Market Landscape
The FDA's action aligns with the agency's broader enforcement of the Federal Food, Drug, and Cosmetic Act regarding regenerative medicine products. It follows established agency protocols for oversight of exosome-based therapies that lack proper biologics license applications.
Operators in the clinical wellness sector should audit their marketing claims to ensure they do not exceed regulatory classifications for biological products. Failure to secure necessary licenses may result in mandatory product cessation or legal action from federal regulators.
The takeaway
The FDA is intensifying its focus on the unauthorized distribution of exosome and umbilical cord-derived products for non-homologous use. Operators should immediately cross-reference their current biological product inventory with active FDA licensure requirements to ensure ongoing compliance.
Further reading
For broader trends in regulatory compliance, see the latest updates in Healthcare.
More information
Review the full FDA public safety notification for exosome products for regulatory context.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you trust medical treatments marketed online that lack formal FDA approval?
